Literature DB >> 34192595

Nanotherapeutic approaches to target mitochondria in cancer.

Shalini Mani1, Geeta Swargiary2, Sakshi Tyagi2, Manisha Singh2, Niraj Kumar Jha3, Keshav K Singh4.   

Abstract

Treatment of cancer cells exemplifies a difficult test in the light of challenges associated with the nature of cancer cells and the severe side effects too. After making a large number of trials using both traditional and advanced therapies (immunotherapy and hormone therapy), approaches to design new therapies have reached a saturation level. However, nanotechnology-based approaches exhibit higher efficacy and great potential to bypass many of such therapeutic limitations. Because of their higher target specificity, the use of nanoparticles offers incredible potential in cancer therapeutics. Mitochondria, acting as a factory of energy production in cells, reveal an important role in the death as well as the survival of cells. Because of its significant involvement in the proliferation of cancer cells, it is being regarded as an important target for cancer therapeutics. Numerous studies reveal that nanotechnology-based approaches to directly target the mitochondria may help in improving the survival rate of cancer patients. In the current study, we have detailed the significance of mitochondria in the development of cancer phenotype, as well as indicated it as the potential targets for cancer therapy. Our study further highlights the importance of different nanoparticle-based approaches to target mitochondria of cancer cells and the associated outcomes of different studies. Though, nanotechnology-based approaches to target mitochondria of cancer cells demonstrate a potential and efficient way in cancer therapeutics. Yet, further study is needed to overcome the linked limitations.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Drug targeting; Mitochondria; Nanoparticles; Therapy

Year:  2021        PMID: 34192595     DOI: 10.1016/j.lfs.2021.119773

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  6 in total

Review 1.  Recent Advances in Carbon Dots for In Vitro/Vivo Fluorescent Bioimaging: A Mini-Review.

Authors:  Chen He; Xiaofeng Lin; Yanqiu Mei; Yan Luo; Min Yang; Ying Kuang; Xiaoqing Yi; Weijia Zeng; Qitong Huang; Bin Zhong
Journal:  Front Chem       Date:  2022-05-05       Impact factor: 5.545

2.  Rational design of large flat nitrogen-doped graphene oxide quantum dots with green-luminescence suitable for biomedical applications.

Authors:  Michael Nazarkovsky; Albina Mikhraliieva; Carlos A Achete; Luiz Anastacio Alves; Joyce Araujo; Bráulio S Archanjo; José Júnior França de Barros; Liana Monteiro da Fonseca Cardoso; José Nelson S S Couceiro; Fernanda Davi Marques; Bruno S Oliveira; Rafael Nascimento Dias de Souza; Ayla Josma Teixeira; Thiago L Vasconcelos; Vladimir Zaitsev
Journal:  RSC Adv       Date:  2022-05-12       Impact factor: 4.036

3.  Synthesis, Biological Activity, and Molecular Modelling Studies of Naphthoquinone Derivatives as Promising Anticancer Candidates Targeting COX-2.

Authors:  Povilas Kavaliauskas; Felipe Stambuk Opazo; Waldo Acevedo; Ruta Petraitiene; Birutė Grybaitė; Kazimieras Anusevičius; Vytautas Mickevičius; Sergey Belyakov; Vidmantas Petraitis
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-27

Review 4.  An Epigenetic Role of Mitochondria in Cancer.

Authors:  Yu'e Liu; Chao Chen; Xinye Wang; Yihong Sun; Jin Zhang; Juxiang Chen; Yufeng Shi
Journal:  Cells       Date:  2022-08-13       Impact factor: 7.666

Review 5.  Nanocarriers: A Reliable Tool for the Delivery of Anticancer Drugs.

Authors:  Hussein Sabit; Mohamed Abdel-Hakeem; Tahsin Shoala; Shaimaa Abdel-Ghany; Mokhtar Mamdouh Abdel-Latif; Jawaher Almulhim; Mohamed Mansy
Journal:  Pharmaceutics       Date:  2022-07-28       Impact factor: 6.525

6.  Identification of SSBP1 as a ferroptosis-related biomarker of glioblastoma based on a novel mitochondria-related gene risk model and in vitro experiments.

Authors:  Jun Su; Yue Li; Qing Liu; Gang Peng; Chaoying Qin; Yang Li
Journal:  J Transl Med       Date:  2022-09-30       Impact factor: 8.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.